Urs Langen (Roche), Katie Planey (Acelot), Neil Cashman (ProMIS™ Neurosciences, Inc.) and 100+ other industry leaders are gearing up to discuss breaking research in neurodegenerative biomarkers, shuttling technologies, clinical subtyping, and new targeting opportunities beyond the recently approved anti-amyloids at the 13th Alzheimer’s & Parkinson’s Drug Development Summit this March. Hear Urs Langen share innovations in second generation antibodies with enhanced BBB penetrance, Katie Planey present the promise of targeting TDP-43 in AD, and Neil Cashman showcase a novel computation method for targeting only the toxic species of amyloid, tau and alpha-synuclein. View the full speaker line-up and industry-dedicated agenda here https://ter.li/z2q6ra. Join us this March for three days of pre-competitive collaboration, cutting-edge data readouts, ample networking opportunities, and more to spearhead a new era of more truly transformative neurodegenerative therapeutics: https://ter.li/u4d4et
关于我们
Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson’s, diabetes and cancer. Acelot’s platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelot’s first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer’s. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.
- 网站
-
http://www.acelot.com
Acelot的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- South San Francisco，California
- 类型
- 私人持股
- 领域
- Alzheimer's disease、drug discovery and development、neurodegenerative diseases、small molecules、machine learning和data science
地点
-
主要
获取路线
329 Oyster Point Blvd
US，California，South San Francisco，94080
Acelot员工
动态
-
Urs Langen (Roche), Katie Planey (Acelot), Neil Cashman (ProMIS™ Neurosciences, Inc.) and 100+ other industry leaders are gearing up to discuss breaking research in neurodegenerative biomarkers, shuttling technologies, clinical subtyping, and new targeting opportunities beyond the recently approved anti-amyloids at the 13th Alzheimer’s & Parkinson’s Drug Development Summit this March. Hear Urs Langen share innovations in second generation antibodies with enhanced BBB penetrance, Katie Planey present the promise of targeting TDP-43 in AD, and Neil Cashman showcase a novel computation method for targeting only the toxic species of amyloid, tau and alpha-synuclein. View the full speaker line-up and industry-dedicated agenda here https://ter.li/z2q6ra. Join us this March for three days of pre-competitive collaboration, cutting-edge data readouts, ample networking opportunities, and more to spearhead a new era of more truly transformative neurodegenerative therapeutics: https://ter.li/u4d4et
-
-
Acelot is proud to present on our ACE-2223 TDP-43 development program for sporadic ALS at the Sachs Neuroscience Innovation Forum this Sunday at 1:20pm PT in San Francisco to kick off JP Morgan week. https://lnkd.in/gPQdHFU4
-
Acelot CEO Dr. Katie Planey has been invited to speak at the ALS One Symposium next Thursday November 14th to discuss progress on Acelot's ACE-2223 TDP-43 development program for the treatment of non genetically associated ALS. Talk is at 10amPT/1pm ET and registration is free https://lnkd.in/gi2yUywH